Advertisement

Picture EBD Group BioPharm America 2018 Boston Partnering 600x60px
Document › Details

IDT Biologika GmbH. (4/24/18). "Press Release: IDT Biologika Acquires Dr. Felgenträger, Located in the BioPharmaPark Dessau". Dessau-Roslau.

Region Region Dessau
  Country Germany
Organisation Organisation IDT Biologika GmbH
  Group Klocke (Group)
Products Product animal vaccine
  Product 2 vaccine
Person Person Kastenbauer, Andreas (Klocke 201701 Managing Director at IDT Biologika)
     


The pharmaceuticals company intends to use this takeover to continue expanding its herd-specific vaccine business


IDT Biologika continues to expand its business with herd-specific vaccines. With the acquisition of “Dr. Felgenträger & Co. Öko-chem. und Pharma GmbH” - a company based at the BioPharmaPark - the vaccine specialist is planning to expand and extend the segment for the manufacture of herd-specific vaccines. The agreement on the takeover of Dr. Felgenträger at the Dessau-Roßlau location was signed at the end of March.

“Dr. Felgenträger has vast experience of almost thirty years in the herd-specific vaccine business. The acquisition therefore represents a key addition to the IDT Biologika business. Both companies can now benefit from their respective strengths and contribute their many years of market experience in differing niche sectors,” explains managing director Andreas Kastenbauer. He added that, with this purchase, IDT has gained not only additional market and product expertise but also a competitor in the field of autogenous vaccines - the term used by specialists for vaccines produced specifically for a particular herd.

“The sector is experiencing strong growth,” adds Dr. Christian Wirth, second managing director and head of the animal health unit at IDT Biologika. With a view to maintaining our ability to meet demand for herd-specific vaccines in the medium term and securing the corresponding level of sales, the only alternative to purchasing additional production capacities would have been to build expensive new facilities. Now, the newly acquired production capacities can be used to bundle activities in this business segment and to further develop the business with herd-specific vaccines. “Therefore, the acquisition is a significant step that constitutes an important part of our animal health operations, today and in the future,” continues Dr. Christian Wirth. Human vaccines, the second pillar of Felgenträger’s operations, but one which is not a strategic fit for IDT Biologika’s business, is to be sold. “The employees in this business segment should have no concerns about job losses, however. They will most certainly be retained,” assures Dr. Wirth.

This is not the first time in recent years that IDT Biologika has expanded its global network for the manufacture of herd-specific vaccines for animal breeders as part of its globalization strategy. Last year, the pharmaceuticals company acquired Ridgeway Biologicals, a UK-based specialist company. In 2015, IDT took over Gallant Custom Laboratories, a manufacturer of herd-specific vaccines based in Canada.


About IDT Biologika

IDT Biologika is an innovative, privately-held company with nearly 100 years of experience in researching, developing, manufacturing and marketing products for the global protection of human and animal health. The company produces vaccines and pharmaceuticals according to the highest quality standards, for its own animal health products and under contract.

Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and the Riems district of Greifswald. IDT's Animal Health business is marketed internationally from its offices in Denmark, the Netherlands, France, Spain, Poland and Canada. In the United States, IDT Corporation operates a production site for clinical test samples in Rockville, Maryland. In Canada, IDT Biologika subsidiary Gallant Custom Laboratories manufactures autogenous vaccines. The same vaccines are produced by the recently acquired IDT subsidiary in the United Kingdom, Ridgeway Biologicals.

In 2017, IDT Biologika registered sales of *€ 241 million ($ 300 million) [* revenue estimated] in animal health and contract manufacturing of vaccines and parenteral products. IDT Biologika currently employs around 2,000 workers worldwide.

IDT Biologika is a member of the Klocke Group, which is specialized in contract production and packaging of medications, vaccines and cosmetic products. As a traditional family-owned company, the Klocke Group employs a workforce of more than 2,500 people at 10 production sites and sales offices around the world. For more information, visit www.idt-biologika.com.


Contact:

IDT Biologika Corporate Communications
Christian Herschel
Am Pharmapark
06861 Dessau-Roßlau
Tel: +49 34901 885 4293
Mob. +49 162 1011442
Email: Christian.Herschel@idt-biologika.de

Web: www.idt-biologika.com

   
Record changed: 2018-05-16

Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px

More documents for Klocke (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2018 Boston Partnering 560x80px




» top